High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma

J. D. Hainsworth, L. S. Burnett, H. W. Jones, W. W. Grosh, D. H. Johnson, F. A. Greco

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


We treated 25 newly diagnosed patients with advanced epithelial ovarian cancer with an intensive induction chemotherapy regimen using high-dose cisplatin in combination with cyclophosphamide and doxorubicin. All patients had either stage IIIC or stage IV disease. Two intensive induction courses of chemotherapy were administered at 28-day intervals, which consisted of cisplatin 40 mg/m2 daily for 5 days, cyclophosphamide 500 mg/m2 day 1, and doxorubicin 40 mg/m2 day 1. Four courses of chemotherapy using cisplatin 60 mg/m2, doxorubicin 40 mg/m2, and cyclophosphamide 500 mg/m2 followed the gh-dose induction therapy. Two of the first six patients died during high-dose induction therapy (one died of neutropenia and sepsis, one of intercurrent intracerebral hemorrhage). Doxorubicin was subsequently omitted from the induction therapy due to unacceptable myelosuppression; no deaths occurred in the remaining 19 patients, and myelosuppression was manageable. Peripheral neuropathy was the most severe side effect with this regimen. This complication was unpredictable, developed during the third or fourth month of treatment, and was disabling in five patients. Other toxicity included prolonged nausea and vomiting (eight patients), ototoxicity (five patients), and nephrotoxicity (two patients), but these did not compromise therapy. All 23 assessable patients had objective response to therapy. Four of 12 patients who underwent second-look laparotomy had pathologic complete response, while four additional patients had only microscopic residual disease. The median survival for the entire group was 25 months. Four patients remain continuously disease-free 23 to 48 months following completion of therapy. Although this regimen was tolerated by most patients, the unpredictable occurrence of disabling neuropathy may limit its usefulness. The median survival in this group of patients with extensive residual disease compares favorably with other reported series; demonstration of any advantage of high-dose cisplatin in ovarian cancer awaits prospective, randomized studies.

Original languageEnglish (US)
Pages (from-to)502-508
Number of pages7
JournalJournal of Clinical Oncology
Issue number3
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this